Point72 Asset Management L.P. Lowers Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Point72 Asset Management L.P. lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 10.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 235,836 shares of the company’s stock after selling 26,564 shares during the period. Point72 Asset Management L.P. owned about 0.48% of Amphastar Pharmaceuticals worth $9,433,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMPH. YHB Investment Advisors Inc. purchased a new position in Amphastar Pharmaceuticals during the 1st quarter valued at about $27,000. Innealta Capital LLC bought a new position in Amphastar Pharmaceuticals in the second quarter worth approximately $55,000. Blue Trust Inc. lifted its holdings in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after buying an additional 309 shares during the period. nVerses Capital LLC boosted its position in Amphastar Pharmaceuticals by 37.5% during the 2nd quarter. nVerses Capital LLC now owns 2,200 shares of the company’s stock valued at $88,000 after acquiring an additional 600 shares in the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at $93,000. Institutional investors own 65.09% of the company’s stock.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 10,282 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at $4,162,175.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the sale, the director now directly owns 33,971 shares of the company’s stock, valued at $1,463,130.97. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 10,282 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at approximately $4,162,175.69. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,383 shares of company stock worth $1,524,123. 27.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Sandler decreased their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $48.53 on Tuesday. The company has a market cap of $2.37 billion, a P/E ratio of 16.79, a price-to-earnings-growth ratio of 0.92 and a beta of 0.82. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The firm’s 50-day moving average price is $45.39 and its 200-day moving average price is $42.71. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The firm had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. As a group, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.